Prognostic value of the MEST-C score in long-term outcomes of immunoglobulin A nephropathy patients: Insights from a developing country

Table 4 Comparison of kidney outcomes with MEST-C score of immunoglobulin A nephropathy at 6 months, 1 year, 2 years, 5 years and 10 years, n (%)

	MEST-C score
	Overall (n = 118)	1 (n = 30)	2 (n = 31)	3 (n = 35)	4 (n = 16)	5 (n = 5)	6 (n = 1)	P value
At 6 months
CR	58 (49.1)	27 (90)	17 (54.8)	11 (31.4)	2 (12.5)	1 (20)	0	0.00
PR	36 (30.5)	3 (10)	14 (45.1)	9 (25.7)	6 (37.5)	4 (80)	0
ESKD	24 (20.3)	0	0	15 (42.8)	8 (50)	0	1 (100)
At 1 year
CR	55 (46.6)	26 (86.6)	15 (48.3)	11 (31.4)	2 (12.5)	1 (20)	0	0.00
PR	37 (31.3)	4 (13.3)	15 (48.3)	8 (22.8)	6 (37.5)	4 (80)	0
ESKD	26 (22.0)	0	1	16 (45.7)	8 (50)	0	1 (100)
At 2 years
CR	54 (45.7)	27 (90)	16 (51.6)	9 (25.7)	2 (12.5)	0	0	0.00
PR	37 (31.3)	3 (10)	14 (45.1)	9 (25.7)	6 (37.5)	5 (100)	0
ESKD	27 (22.8)	0	1 (3.2)	17 (48.5)	8 (50)	0	1 (100)
At 3 years
CR	22 (18.6)	8 (26.6)	10 (32.2)	3 (8.5)	1 (6.2)	0	0	0.00
PR	21 (17.7)	1 (3.3)	7 (22.5)	9 (25.7)	3 (18.7)	1 (20)	0
ESKD	36 (30.5)	0	5 (16.1)	17 (48.5)	10 (62.5)	3 (60)	1 (100)
Lost-to-F/U	39 (33.0)	21 (70)	9 (29.0)	6 (17.1)	2 (12.5)	1 (20)	0
At 5 years
CR	17 (14.4)	6 (20)	8 (25.8)	2 (5.7)	1 (6.2)	0	0	0.00
PR	19 (16.1)	2 (6.6)	7 (22.5)	8 (22.8)	1 (6.2)	1 (20)	0
ESKD	37 (31.3)	0	6 (19.3)	17 (48.5)	10 (62.5)	3 (60)	1 (100)
Lost-to-F/U	45 (38.1)	22 (73.3)	10 (32.2)	8 (22.8)	4 (25)	1 (20)	0
At 10 years
CR	8 (6.7)	3 (10)	4 (12.9)	0	1 (6.2)	0	0	0.00
PR	12 (10.1)	3 (10)	4 (12.9)	5 (14.2)	0	0	0
ESKD	40 (33.8)	0	6 (19.3)	18 (51.4)	12 (75)	3 (60)	1 (100)
Lost-to-F/U	58 (49.1)	24 (80)	17 (19.3)	12 (34.2)	3 (18.7)	2 (40)	0

CR: Complete remission; PR: Partial remission; ESKD: End stage kidney disease; F/U: Follow-up.